The Committee holds an Executive Session entitled, “Authorization for Investigation into the High Costs of Prescription Drugs and Related Subpeonas” with CEO Duato of Johnson & Johnson and CEO Davis of Merck on January 31 at 11:00 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Nanobiotixachieves $20M milestone payment from Johnson & Johnson subsidiary
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- JNJ Stock: What to Consider Before Its Next Dividend Hike
- Capital One says buy these six biotech stocks for 2024
- J&J to pay $149.5M to Washington state over role in opioid epidemic